COMMUNIQUÉS West-GlobeNewswire

GENFIT: HALF-YEAR REPORT OF LIQUIDITY CONTRACT WITH CIC

10/07/2017 - 17:50

GENFIT: HALF-YEAR REPORT OF LIQUIDITY CONTRACT WITH CIC Lille (France), Cambridge (Massachusetts, United States), July 10, 2017 - GENFIT (Euronext: GNFT - ISIN: FR0004163111), a biopharmaceutical company at the [...]

Medtronic Expands TAVR Access to More Patients With Symptomatic, Severe Aortic Stenosis Upon Intermediate Risk FDA Approval

10/07/2017 - 17:35

Self-Expanding CoreValve(TM) Evolut(TM)TAVR Platform with Excellent Procedural Safety and Proven Valve Performance Helps Address Needs of Intermediate-Risk Patients DUBLIN - July 10, 2017 - Medtronic plc (NYSE: MDT) [...]

Sanofi Genzyme and Alnylam Report Positive Results from Ongoing phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or...

10/07/2017 - 15:30

Sanofi Genzyme and Alnylam Report Positive Results from Ongoing phase 2 Open-Label Extension Study with Investigational RNAi Therapeutic Fitusiran in Patients with Hemophilia A and B With or Without Inhibitors - With up [...]

Sanofi Genzyme et Alnylam présentent les résultats positifs de l'étude de prolongation de phase 2 en ouvert portant sur le fitusiran, un agent thérapeutique expérimental ARNi, chez des patients...

10/07/2017 - 15:30

Sanofi Genzyme et Alnylam présentent les résultats positifs de l'étude de prolongation de phase 2 en ouvert portant sur le fitusiran, un agent thérapeutique expérimental ARNi, chez des patients atteints d'hémophilie A [...]

AC IMMUNE PROVIDES SEVEN UPDATES ON ITS PIPELINE AND TECHNOLOGY AT THE ALZHEIMER'S ASSOCIATION INTERNATIONAL CONFERENCE

10/07/2017 - 13:55

Lausanne, Switzerland, July 10, 2017 - AC Immune SA (NASDAQ: ACIU), a Swiss-based, clinical stage biopharmaceutical company focused on neurodegenerative diseases, today announced that seven updates on the advancement of [...]

ProMIS Neurosciences Provides Second Quarter Update for 2017 and Outlook for Near-Term Value Creation

10/07/2017 - 13:30

Updated corporate overview available on ProMIS website TORONTO and CAMBRIDGE, Mass., July 10, 2017 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc., a biotechnology company focused on the discovery and development of [...]

Virbac : Déclaration d'actions et de droits de vote au 30 Juin 2017

10/07/2017 - 10:56

DECLARATION D'ACTIONS ET DE DROITS DE VOTE Informations relatives au nombre total de droits de vote et au nombre d'actions composant le capital (Article 223-16 du Règlement Général de l'Autorité des Marchés Financiers) [...]

Virbac : Declaration of the number of shares and voting rights as of June 2017, 30.

10/07/2017 - 10:56

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital (Article 223-16 of the General regulations of the French Financial [...]

PCI Biotech: Extension of preclinical research collaboration agreement with a top-10 large pharma company

10/07/2017 - 08:00

Oslo (Norway), 10 July 2017 - PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company today announced that they are extending the preclinical research collaboration with an undisclosed top-10 pharma company [...]

ThromboGenics and BioInvent Amending Long-Standing Monoclonal Antibody Development Agreement

10/07/2017 - 07:30

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients. The issuer of this announcement warrants that they are solely responsible for the content, accuracy [...]

Biocartis Group NV: Biocartis and A*STAR's ETPL initiate development of breast cancer assay to guide therapy selection

10/07/2017 - 07:00

PRESS RELEASE: 10 July 2017, 07:00 CEST Biocartis and A*STAR's ETPL initiate development of breast cancer assay to guide therapy selection Singapore / Mechelen (Belgium) , 10 July 2017 - Biocartis Group NV ('Biocartis' [...]

SelectMDx to be Distributed Across Middle East by IPS Genomix

10/07/2017 - 07:00

MDxHealth establishes commercial agreement with regional experts NEWS RELEASE / REGULATED INFORMATION / INSIDE INFORMATION HERSTAL, BELGIUM - July 10, 2017 - MDxHealth SA (Euronext: MDXH.BR) today announced that it has [...]

IPS GenomiX devient distributeur de SelectMDx au Moyen-Orient

10/07/2017 - 07:00

MDxHealth a établi un accord commercial avec des experts régionaux COMMUNIQUE DE PRESSE / INFORMATION REGLEMENTAIRE / INFORMATION PRIVILEGIEE HERSTAL, BELGIQUE - 10 juillet 2017 - MDxHealth SA (Euronext : MDXH.BR) a [...]

Guerbet annonce un plan de rationalisation de sa gamme de produits de contraste

10/07/2017 - 07:00

Villepinte, le 10 juillet 2017 (7h00) - Guerbet (FR0000032526 GBT), spécialiste mondial des produits de contraste et solutions pour l'imagerie médicale, annonce aujourd'hui qu'il va cesser progressivement la [...]

Guerbet Announces Plans to Streamline Its Contrast Media Portfolio

10/07/2017 - 07:00

Villepinte (France), July 10, 2017 (7:00 AM CET) - Guerbet (FR0000032526 GBT), the global specialist in contrast products and solutions for medical imaging, announced today that it will phase out sales throughout the [...]

Guerbet Announces Plans to Streamline Its Contrast Media Portfolio

10/07/2017 - 07:00

Villepinte (France), July 10, 2017 (7:00 AM CET) - Guerbet (FR0000032526 GBT), the global specialist in contrast products and solutions for medical imaging, announced today that it will phase out sales throughout the [...]

Merus to Report First Quarter 2017 Financial & Mid-Year Operating Results on July 11, 2017

07/07/2017 - 17:51

Conference call and webcast scheduled on 4:30pm ET UTRECHT, The Netherlands, July 06, 2017 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq:MRUS), a clinical-stage immuno-oncology company developing innovative bispecific antibody [...]

Merus communiquera les résultats financiers du premier trimestre 2017 et les résultats d'exploitation de mi exercice le 11 juillet 2017

07/07/2017 - 17:51

Conférence téléphonique et diffusion sur le Web prévues à 16 h 30 HNE UTRECHT, Pays-Bas, le 6 juillet 2017 (GLOBE NEWSWIRE) - Merus N.V. (Nasdaq:MRUS), une société d'immuno-oncologie de stade clinique qui développe des [...]

MPI: Oncology Venture and Eisai Forge Exclusive Global License Agreement for Clinical Stage Oncology Drug PARP Inhibitor E7449 - 2X-121

07/07/2017 - 14:30

2X Oncology to conduct Phase 2 Study of 2X-121 in metastatic breast cancer patients Hoersholm, Denmark, and Cambridge, MA, July 7, 2017 - Oncology Venture AB ("Oncology Venture") and 2X Oncology Inc. ("2X Oncology"), [...]